Pair page
Cerebrolysin with Dihexa
Mechanism-tag overlap and published literature for Cerebrolysin and Dihexa, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
neurotrophic-brain-bioregulator
angiotensin-iv-analog-hgf-positive-modulatorpeptidomimetic
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Cerebrolysin and Dihexa have published these mechanism-level observations. Not a co-administration recommendation.
Porcine brain peptide hydrolysate with 200+ clinical trials in stroke and dementia. A more evidence-backed neurotrophic-class alternative to dihexa for users seeking that biological category. Available in many ex-US markets.
Quick facts
Cerebrolysin
Dihexa
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2021 | Cerebrolysin | Vester JC, Buzoianu AD, Florian SI, Hömberg V, Kim SH, Lee TMC, Matula C, Poon WS, von Steinbüchel N, Strilciuc S, von Wild K, Muresanu D. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021;42(2):… PMID 33620612 | meta-analysis |
| 2018 | Cerebrolysin | Bornstein NM, Guekht A, Vester J, Heiss WD, Gusev E, Hömberg V, Rahlfs VW, Bajenaru O, Popescu BO, Muresanu D. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018;39(4):629-640. PMID: 29248999. PMID 29248999 | meta-analysis |
| 2015 | Cerebrolysin | Gauthier S, Proaño JV, Jia J, Froelich L, Vester JC, Doppler E. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015;39(5-6):332-347. PMID: 25832905. PMID 25832905 | meta-analysis |
| 2020 | Cerebrolysin | Poon W, Vos P, Muresanu D, Vester J, von Wild K, Hömberg V, et al. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I — a randomized, placebo-controlled, double-blind, Asian-Pacific trial. Neurol Sci. 2020;41(2):281-293. PMID: 31494820. PMID 31494820 | human trial |
| 2020 | Cerebrolysin | Woo PYM, Ho JWK, Ko NMW, Li RPT, Jian L, Chu ACH, Kwan MCL, Chan Y, Wong AKS, Wong HT, Chan KY, Kwok JCK. Randomized, placebo-controlled, double-blind, pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage. BMC Neurol.… PMID 33143640 | human trial |
| 2017 | Cerebrolysin | Gharagozli K, Harandi AA, Houshmand S, Akbari N, Muresanu DF, Vester J, Winter S, Moessler H. Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial. J Med Life. 20… PMID 29075343 | human trial |
| 2016 | Cerebrolysin | Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Popescu CD, Vester JC, Rahlfs VW, Doppler E, Meier D, Moessler H, Guekht A. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016;47(1):151-159. PMID: 26564102. PMID 26564102 | human trial |
| 2016 | Cerebrolysin | Hassanein SM, Deifalla SM, El-Houssinie M, Mokbel SA. Safety and Efficacy of Cerebrolysin in Infants with Communication Defects due to Severe Perinatal Brain Insult: A Randomized Controlled Clinical Trial. J Clin Neurol. 2016;12(1):79-84. PMID: 26365023. PMID 26365023 | human trial |
| 2012 | Cerebrolysin | Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z; Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012;43(3):630-636. PM… PMID 22282884 | human trial |
| 2010 | Cerebrolysin | Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of Cerebrolysin in patients with acute ischaemic stroke in Asia — CASTA. Int J Stroke. 2010;5(4):310-313. PMID: 19765131. PMID 19765131 | human trial |
| 2005 | Cerebrolysin | Ladurner G, Kalvach P, Moessler H; Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. J Neural Transm (Vienna). 2005;112(3):415-428. PMID: 15583955. PMID 15583955 | human trial |
| 2023 | Cerebrolysin | Rejdak K, Sienkiewicz-Jarosz H, Bienkowski P, Alvarez A. Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin. Med Res Rev. 2023;43(5):1668-1700. PMID: 37052231. PMID 37052231 | human study |
| 2024 | Dihexa | Athira Pharma, Inc. Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease. Press release, late 2024. (NCT04488419 — primary endpoint not met.) | human trial, Phase 2 |
| 2023 | Dihexa | Athira Pharma, Inc. Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton in Parkinson's Disease Dementia and Dementia with Lewy Bodies. Press release, December 2023. (NCT04831281.) | human trial, Phase 2 |
| 2022 | Dihexa | Athira Pharma, Inc. Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease. Press release, 2022. (NCT04491006.) | human trial, Phase 2 |
| — | Dihexa | Hua X, Church K, Walker W, L'Hostis P, Viardot G, Danjou P, Hendrix S, Moebius HJ. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease. (Fosgonimeton Phase 1… | human trial, Phase 1 |
| 2015 | Dihexa | Wright JW, Harding JW. The brain hepatocyte growth factor/c-Met receptor system: A new target for the treatment of Alzheimer's disease. J Alzheimers Dis. 2015;45(4):985-1000. PMID: 25649658. (Mechanistic review.) PMID 25649658 | human study |
| 2021 | Dihexa | Sun X, Deng Y, Liang J, Lin Y, Song J, Zhao S, Zhuang G, Jia Z. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Sci. 2021 Oct 28;11(11):1421. PMID: 34827487. (Independent Chinese group; APP/PS1 m… PMID 34827487 | preclinical, in vivo |
| 2025 | Dihexa | FDA. Bulk Drug Substances Nominated for Use in Compounding — 503A and 503B Categories. FDA.gov. Updated 2025–2026. | regulatory / registry |
| 2022 | Dihexa | Stem Cell Research & Therapy. Dihexa as adjunct in peripheral nerve repair. 2022 Apr 11;13(1):159. PMID: 35410439. PMCID: PMC8996222. PMID 35410439 | research article |
| 2015 | Dihexa | Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Prog Neurobiol. 2015 Feb;125:26-46. PMID: 25455861. (Comprehensive Wright/Harding review.) PMID 25455861 | research article |
| 2015 | Dihexa | Uribe PM, Kawas LH, Harding JW, Coffin AB. Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure. Front Cell Neurosci. 2015 Jan 28;9:3. PMID: 25674052. PMCID: PMC4309183. (Independent dihexa hair-cell preservation study.) PMID 25674052 | research article |
| 2015 | Dihexa | Siller R, Greenhough S, Naumovska E, Sullivan GJ. Small-molecule-driven hepatocyte differentiation of human pluripotent stem cells. Stem Cell Reports. 2015 May 12;4(5):939-52. PMID: 25937370. PMID 25937370 | research article |
| 2014 | Dihexa | Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, Wright JW, Wayman GA, Harding JW. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther. 2014… PMID 25187433 | research article |
Related pair pages
More research context
Frequently asked
Have Cerebrolysin and Dihexa been studied together?
Researchers have published mechanistic-level co-administration discussion of Cerebrolysin and Dihexa. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Cerebrolysin and Dihexa share?
Cerebrolysin and Dihexa do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Cerebrolysin and Dihexa?
Cerebrolysin: Not approved (US). Dihexa: Investigational / Research only. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Cerebrolysin and Dihexa?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Cerebrolysin profile and the Dihexa profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026